Skip to main content
. 2023 Oct 27;11(3):249–254. doi: 10.1093/nop/npad071

Table 1.

Comparison of Patient Characteristics, Treatment Volumes, and OARs Dosimetric Parameters in the CTV20 and CTV15 Groups

CTV20 group CTV15 group P
N 57 56
Age (years) median (range) 56.4 (33–70) 55.1 (25–70) .47*
Sex (male) n (%) 44 (77.2%) 37 (66.1%) .22
Tumor side (left) n (%) 38 (66.7%) 31 (55.4%) .25
MGMT methylated n (%) 29 (50.9%) 25 (44.6%) .57
IDH mutated n (%) 4 (7.0%) 6 (10.7%) .53
Biopsy only n (%) 19 (33.3%) 15 (26.8%) .54
WHO performance status
- 0–1
- 2
- 3
n (%) 42 (73.6%)
14 (24.6%)
1 (1.8%)
44 (78.6%)
12 (21.4%)
0
.45
GTV (cm3) mean ± SD 39.7 ± 29.0 37.8 ± 23.8 .71*
CTV (cm3) mean ± SD 238.9 ± 108.3 176. 7 ± 73.2 .001 *
PTV (cm3) mean ± SD 292.6 ± 124.1 217.0 ± 84.0 <.001 *
Brain Dmean (Gy) mean ± SD 25.2 ± 7.8 21.0 ± 6.2 .002 *
Hippocampus R Dmean (Gy) median (IQR) 11.8 (5.4–26.8) 7.1 (3.7–49.1) .20
Hippocampus L Dmean (Gy) median (IQR) 43.7 (6.7–59.2) 10.6 (6.0–51.8) .04
Hippocampi Dmean (Gy) median (IQR) 28.9 (14.7–34.9) 26.4 (5.4–32.6) .13
Brainstem D0.03cc (Gy) median (IQR) 58.8 (36.4–60.2) 54.1 (24.7–57.8) <.001
Optic nerve R D0.03cc (Gy) median (IQR) 21.6 (9.4–50.1) 17.4 (6.0–42.3) .24
Optic nerve L D0.03cc c (Gy) median (IQR) 34.5 (11.4–51.3) 16.0 (8.1–43.7) .14
Optic chiasm D0.03cc (Gy) median (IQR) 30.1 (15.8–53.3) 24.8 (9.3–53.9) .37
Cochlea R Dmean (Gy) median (IQR) 6.3 (1.8–13.4) 2.7 (0.8–8.4) .01
Cochlea L Dmean (Gy) median (IQR) 9.4 (2.8–29.8) 2.5 (0.9–11.1) .001
Pituitary Gland Dmean (Gy) median (IQR) 31.9 (7.9–40.3) 13.8 (2.4–26.5) .006

* P-value from t-test; P-value from chi-square test; P-value from Mann–Whitney test.

Abbreviations: L, left; R, right; Dmean, mean dose; D0.03cc, dose to 0.03cc; OS, overall survival; PFS, progression-free survival; CTV, clinical target volume.